Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The MOU establishes a framework in which the two companies will enter into a strategic partnership to explore potential genomic biomarkers of the tumor microenvironment in an early-phase trial of the investigational compound GI-101.
Lead Product(s): GI-101,Pembrolizumab
Therapeutic Area: Oncology Product Name: GI-101
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Agilent Technology Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 02, 2020